MARKET

CDNA

CDNA

Caredx
NASDAQ
15.83
+0.26
+1.67%
After Hours: 16.09 +0.26 +1.64% 18:47 05/23 EDT
OPEN
15.66
PREV CLOSE
15.57
HIGH
16.54
LOW
15.01
VOLUME
1.22M
TURNOVER
0
52 WEEK HIGH
16.54
52 WEEK LOW
4.800
MARKET CAP
824.49M
P/E (TTM)
-4.6133
1D
5D
1M
3M
1Y
5Y
Weekly Report: what happened at CDNA last week (0513-0517)?
Weekly Report · 3d ago
CareDx Price Target Raised to $22.00/Share From $15.00 by Craig-Hallum
Dow Jones · 6d ago
CareDx Is Maintained at Buy by Craig-Hallum
Dow Jones · 6d ago
Analysts Offer Insights on Healthcare Companies: CareDx (CDNA), Amgen (AMGN) and Orasure Technologies (OSUR)
TipRanks · 6d ago
Craig-Hallum Maintains Buy on CareDx, Raises Price Target to $22
Benzinga · 6d ago
CAREDX, INC. <CDNA.O> : CRAIG-HALLUM RAISES TARGET PRICE TO $22 FROM $15
Reuters · 6d ago
U.S. RESEARCH ROUNDUP-Bath & Body Works, Under Armour, Viking Therapeutics
Reuters · 6d ago
CareDx Presents Findings from The SHORE Study, HeartCare Outperforms dd-cfDNA Alone In Identifying Rejection And Patients Experienced Fewer Biopsies
HeartCare Results Effectively Stratified Patients at Highest Risk for Acute Cellular Rejection Cardiologists Performed the Fewest Biopsies after Dual Negative HeartCare Results Compared to Single or Dual Positive Results. Two-year Clinical Outcomes Data Demonstrate Excellent Survival and Allograft Function. HeartCare is one of the largest heart transplant studies of its kind.
Benzinga · 05/16 20:24
More
About CDNA
CareDx, Inc. is a precision medicine solutions company. The Company is focused on the discovery, development, and commercialization of clinically differentiated, diagnostic solutions for transplant patients and caregivers. The Company offers testing services, products, and patient and digital solutions along the pre- and post-transplant patient journey and is a provider of genomics-based information for transplant patients. Its commercially available testing services consist of AlloSure Kidney, a donor-derived cell-free DNA (dd-cfDNA) solution for kidney transplant patients; AlloMap Heart, a gene expression solution for heart transplant patients; AlloSure Heart, a dd-cfDNA solution for heart transplant patients, and AlloSure Lung, a dd-cfDNA solution for lung transplant patients. The Company’s product portfolio includes AlloSeq Tx, QTYPE, Olerup SSP, AlloSeq HCT and AlloSeq cfDNA. It develops and provides diagnostic surveillance testing services for various transplant recipients.

Webull offers CareDx Inc stock information, including NASDAQ: CDNA real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, CDNA stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading CDNA stock methods without spending real money on the virtual paper trading platform.